Condition: Breast Cancer · Sponsor: Hoffmann-La Roche
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).
This description comes directly from the study's public registry record.
Reference Study ID Number: WO45654 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| The Dignity Health Cancer Institute | Phoenix, Arizona, United States | Recruiting |
| Disney Family Cancer Center | Burbank, California, United States | Recruiting |
| Scripps Health | La Jolla, California, United States | Recruiting |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Recruiting |
| Ellison Institute of Technology | Los Angeles, California, United States | Recruiting |
| Palo Alto Medical Foundation Research Center | Palo Alto, California, United States | Recruiting |
| Kaiser Permanente - San Marcos | San Marcos, California, United States | Recruiting |
| Palo Alto Medical Foundation Research Center | San Mateo, California, United States | Recruiting |
| Palo Alto Medical Foundation Research Center | Sunnyvale, California, United States | Recruiting |
| Cancer Specialists of North Florida - Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Tallahassee Memorial HealthCare | Tallahassee, Florida, United States | Recruiting |
| Moffitt Cancer Center-McKinley Campus | Tampa, Florida, United States | Recruiting |
+ 220 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06790693